Insights in Oncology
Insights in Oncology
PEARL A.I. apply Artificial Intelligence and Bioinformatics techniques to analyse genomic and associated data and develop deep knowledge-driven models that define the genetic and functional changes occurring in cancer cells. We use these to :
-
determine personalised therapeutic approaches for individual cancer patients,
-
identify novel therapeutic targets for cancer drug discovery.
Companion Diagnostic
Our companion diagnostic A.I. system is designed to help oncologists construct personalised therapeutic regimes for their patients, utilising DNA sequences from the individual patient's tumour sample, to identify what targeted drugs will be of most benefit at each stage of their disease, thereby optimising the efficacy of treatment and minimising unnecessary side effects.
Founders
Expert in identifying therapeutic vulnerabilities in cancer. Over 20 years experience developing software solutions including A.I. and BIG data. Head of the Bioinformatics Lab at the University of Sussex.
Prof. Laurence Pearl FRS FMedSci
Expert in cancer molecular biology and drug discovery. Head of Structural Biology at The Institute of Cancer Research. Professor of Structural Biology at the University of Sussex. Founder and non-executive director of Domainex Ltd.
Contact Us
PEARL A.I. are actively seeking partners and investment to help bring our innovative companion diagnostic to market. Email frances@pearlai.co.uk to arrange a call.